Table 1. Patient-, Disease-, and... | American Society of Hematology

Table 1.

Patient-, Disease-, and Transplant-Related Characteristics of 113 Recipients of HLA-Identical Sibling Bone Marrow Transplants for Low-Grade Non-Hodgkin’s Lymphoma Reported to the IBMTR by 50 Centers Worldwide

Variable	No. Assessable	Patients
Variable	No. Assessable	No.	%
Patient characteristics
Male gender	113	66	58
Age at transplant (yr)	113
Median		38
Range		15-61
<40		63	56
≥40		50	44
KPS ≤ 80%	113	33	29
Disease characteristics at diagnosis
Histology	113
Small lymphocytic		20	18
Follicular small cleaved		52	46
Follicular mixed		41	36
Disease stage	113
I		2	2
II		9	8
III		10	9
IV		92	81
Extranodal involvement	110
None		19	17
Bone marrow		66	60
Bone marrow + other^-150		13	12
Other^-150		12	11
Disease characteristics at transplant
Disease stage	113
Complete remission		16	14
I		2	2
II		7	6
III		7	6
IV		80	71
Unknown		1	1
Extranodal involvement	110
None		30	27
Bone marrow		64	58
Bone marrow + other^-151		11	10
Other^-151		5	5
Response to chemotherapy	105
Sensitive		66	63
Resistant		39	37
No. of prior chemotherapy regimens	110
Median		2
Range		1-5
Prior complete remission	112	46	41
Disease duration (mo)	113
Median		24
Range		5-130
Transplant characteristics
Year of transplant	113
1984-1987		3	3
1988-1989		15	13
1990-1991		23	20
1992-1993		35	31
1994-1995		37	33
Donor-recipient sex match	113
Male-male		35	31
Male-female		29	26
Female-male		30	27
Female-female		19	16
Donor-recipient CMV status	109
+/+		36	33
−/+		19	17
Donor-recipient CMV status (Cont’d)
+/−		21	19
−/−		33	30
Conditioning regimen	113
TBI + Cy		32	28
TBI + Cy + VP16 ± other		43	38
TBI + Cy + other (not VP16)		11	10
TBI ± other		7	6
LFR + Cy + Bu		1	1
Cy + BCNU + VP16		1	1
Cy + Bu		15	13
Other		3	3
GVHD prophylaxis	113
MTX + CsA ± other		68	60
MTX ± other		2	2
CsA ± other		17	15
T-cell depletion ± other		25	22
FK506 + corticosteroids		1	1

Variable	No. Assessable	Patients
Variable	No. Assessable	No.	%
Patient characteristics
Male gender	113	66	58
Age at transplant (yr)	113
Median		38
Range		15-61
<40		63	56
≥40		50	44
KPS ≤ 80%	113	33	29
Disease characteristics at diagnosis
Histology	113
Small lymphocytic		20	18
Follicular small cleaved		52	46
Follicular mixed		41	36
Disease stage	113
I		2	2
II		9	8
III		10	9
IV		92	81
Extranodal involvement	110
None		19	17
Bone marrow		66	60
Bone marrow + other^-150		13	12
Other^-150		12	11
Disease characteristics at transplant
Disease stage	113
Complete remission		16	14
I		2	2
II		7	6
III		7	6
IV		80	71
Unknown		1	1
Extranodal involvement	110
None		30	27
Bone marrow		64	58
Bone marrow + other^-151		11	10
Other^-151		5	5
Response to chemotherapy	105
Sensitive		66	63
Resistant		39	37
No. of prior chemotherapy regimens	110
Median		2
Range		1-5
Prior complete remission	112	46	41
Disease duration (mo)	113
Median		24
Range		5-130
Transplant characteristics
Year of transplant	113
1984-1987		3	3
1988-1989		15	13
1990-1991		23	20
1992-1993		35	31
1994-1995		37	33
Donor-recipient sex match	113
Male-male		35	31
Male-female		29	26
Female-male		30	27
Female-female		19	16
Donor-recipient CMV status	109
+/+		36	33
−/+		19	17
Donor-recipient CMV status (Cont’d)
+/−		21	19
−/−		33	30
Conditioning regimen	113
TBI + Cy		32	28
TBI + Cy + VP16 ± other		43	38
TBI + Cy + other (not VP16)		11	10
TBI ± other		7	6
LFR + Cy + Bu		1	1
Cy + BCNU + VP16		1	1
Cy + Bu		15	13
Other		3	3
GVHD prophylaxis	113
MTX + CsA ± other		68	60
MTX ± other		2	2
CsA ± other		17	15
T-cell depletion ± other		25	22
FK506 + corticosteroids		1	1

Abbreviations: KPS, Karnovsky performance score; CMV, cytomegalovirus; TBI, total-body irradiation; Cy, cyclophosphamide; VP16, etoposide; LFR, limited-field radiation; Bu, busulfan; BCNU, nitrosurea; MTX, methotrexate; CsA, cyclosporine.

F0-150

Other = pleura, liver, bone, skin, lung, kidney, epidural space.

F0-151

Other = pleura, liver, kidney, bone, lung, brain.

View Large

This Feature Is Available To Subscribers Only